177 related articles for article (PubMed ID: 36050267)
1. PD-L1/PD-L1 signalling promotes colorectal cancer cell migration ability through RAS/MEK/ERK.
Cao Y; Liang W; Fang L; Liu MK; Zuo J; Peng YL; Shan JJ; Sun RX; Zhao J; Wang J
Clin Exp Pharmacol Physiol; 2022 Dec; 49(12):1281-1293. PubMed ID: 36050267
[TBL] [Abstract][Full Text] [Related]
2. PD-L1 confers glioblastoma multiforme malignancy via Ras binding and Ras/Erk/EMT activation.
Qiu XY; Hu DX; Chen WQ; Chen RQ; Qian SR; Li CY; Li YJ; Xiong XX; Liu D; Pan F; Yu SB; Chen XQ
Biochim Biophys Acta Mol Basis Dis; 2018 May; 1864(5 Pt A):1754-1769. PubMed ID: 29510196
[TBL] [Abstract][Full Text] [Related]
3. Cancer cell-intrinsic expression of MHC II in lung cancer cell lines is actively restricted by MEK/ERK signaling and epigenetic mechanisms.
Neuwelt AJ; Kimball AK; Johnson AM; Arnold BW; Bullock BL; Kaspar RE; Kleczko EK; Kwak JW; Wu MH; Heasley LE; Doebele RC; Li HY; Nemenoff RA; Clambey ET
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32312906
[TBL] [Abstract][Full Text] [Related]
4. An increase in BAG-1 by PD-L1 confers resistance to tyrosine kinase inhibitor in non-small cell lung cancer via persistent activation of ERK signalling.
Lin PL; Wu TC; Wu DW; Wang L; Chen CY; Lee H
Eur J Cancer; 2017 Nov; 85():95-105. PubMed ID: 28892778
[TBL] [Abstract][Full Text] [Related]
5. Krill oil extract inhibits the migration of human colorectal cancer cells and down-regulates EGFR signalling and PD-L1 expression.
Jayathilake AG; Veale MF; Luwor RB; Nurgali K; Su XQ
BMC Complement Med Ther; 2020 Dec; 20(1):372. PubMed ID: 33287803
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-124-3p suppresses PD-L1 expression and inhibits tumorigenesis of colorectal cancer cells via modulating STAT3 signaling.
Roshani Asl E; Rasmi Y; Baradaran B
J Cell Physiol; 2021 Oct; 236(10):7071-7087. PubMed ID: 33821473
[TBL] [Abstract][Full Text] [Related]
7. FGFR2 Promotes Expression of PD-L1 in Colorectal Cancer via the JAK/STAT3 Signaling Pathway.
Li P; Huang T; Zou Q; Liu D; Wang Y; Tan X; Wei Y; Qiu H
J Immunol; 2019 May; 202(10):3065-3075. PubMed ID: 30979816
[TBL] [Abstract][Full Text] [Related]
8. Distinct roles of programmed death ligand 1 alternative splicing isoforms in colorectal cancer.
Wang C; Weng M; Xia S; Zhang M; Chen C; Tang J; Huang D; Yu H; Sun W; Zhang H; Lai M
Cancer Sci; 2021 Jan; 112(1):178-193. PubMed ID: 33058325
[TBL] [Abstract][Full Text] [Related]
9. PD-L1 Expression Promotes Epithelial to Mesenchymal Transition in Human Esophageal Cancer.
Chen L; Xiong Y; Li J; Zheng X; Zhou Q; Turner A; Wu C; Lu B; Jiang J
Cell Physiol Biochem; 2017; 42(6):2267-2280. PubMed ID: 28848143
[TBL] [Abstract][Full Text] [Related]
10. PD-L1 promotes colorectal cancer stem cell expansion by activating HMGA1-dependent signaling pathways.
Wei F; Zhang T; Deng SC; Wei JC; Yang P; Wang Q; Chen ZP; Li WL; Chen HC; Hu H; Cao J
Cancer Lett; 2019 May; 450():1-13. PubMed ID: 30776481
[TBL] [Abstract][Full Text] [Related]
11. Cholinergic signaling influences the expression of immune checkpoint inhibitors, PD-L1 and PD-L2, and tumor hallmarks in human colorectal cancer tissues and cell lines.
Kuol N; Godlewski J; Kmiec Z; Vogrin S; Fraser S; Apostolopoulos V; Nurgali K
BMC Cancer; 2023 Oct; 23(1):971. PubMed ID: 37828429
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-93-5p expression in tumor tissue and its tumor suppressor function via targeting programmed death ligand-1 in colorectal cancer.
Chen YL; Wang GX; Lin BA; Huang JS
Cell Biol Int; 2020 May; 44(5):1224-1236. PubMed ID: 32068322
[TBL] [Abstract][Full Text] [Related]
13. Upregulated LINC01088 facilitates malignant phenotypes and immune escape of colorectal cancer by regulating microRNAs/G3BP1/PD-L1 axis.
Li C; Pan B; Wang X; Liu X; Qin J; Gao T; Sun H; Pan Y; Wang S
J Cancer Res Clin Oncol; 2022 Aug; 148(8):1965-1982. PubMed ID: 35357586
[TBL] [Abstract][Full Text] [Related]
14. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
Marginean EC; Melosky B
Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
[TBL] [Abstract][Full Text] [Related]
15. Silencing of linc00337 inhibits proliferation, cell cycle progression, migration, and invasion of colorectal cancer cells through the MEK/ERK pathway.
Wang ZG; Yang YG; Fu GS; Lu DH; Tian SY; Wei W
Eur Rev Med Pharmacol Sci; 2020 May; 24(10):5353-5359. PubMed ID: 32495869
[TBL] [Abstract][Full Text] [Related]
16. Relationships among
Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
[TBL] [Abstract][Full Text] [Related]
17. RAS-Mitogen-Activated Protein Kinase Signal Is Required for Enhanced PD-L1 Expression in Human Lung Cancers.
Sumimoto H; Takano A; Teramoto K; Daigo Y
PLoS One; 2016; 11(11):e0166626. PubMed ID: 27846317
[TBL] [Abstract][Full Text] [Related]
18. Nuclear PD-L1 promotes cell cycle progression of BRAF-mutated colorectal cancer by inhibiting THRAP3.
Ma R; Liu Y; Che X; Li C; Wen T; Hou K; Qu X
Cancer Lett; 2022 Feb; 527():127-139. PubMed ID: 34923044
[TBL] [Abstract][Full Text] [Related]
19. KRAS G12V mutation upregulates PD-L1 expression via TGF-β/EMT signaling pathway in human non-small-cell lung cancer.
Pan LN; Ma YF; Li Z; Hu JA; Xu ZH
Cell Biol Int; 2021 Apr; 45(4):795-803. PubMed ID: 33325140
[TBL] [Abstract][Full Text] [Related]
20. Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression.
Napolitano S; Matrone N; Muddassir AL; Martini G; Sorokin A; De Falco V; Giunta EF; Ciardiello D; Martinelli E; Belli V; Furia M; Kopetz S; Morgillo F; Ciardiello F; Troiani T
J Exp Clin Cancer Res; 2019 Dec; 38(1):492. PubMed ID: 31842958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
